The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia

Psychiatry Research

Volumn 189, Issue 1, 2011, Pages 72-76

  Xiong, Peng ^a,b   Zeng, Yong ^a   Wan, Jing ^a,c   XiaoHan, Diana Huang ^d   Tan, Deyong ^b   Lu, Jin ^a   Xu, Fei ^a   Li, Hong yi ^a   Zhu, Zuxin ^a   Ma, Mingxing ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b YUNNAN UNIVERSITY   (China)

^c Clinical Psychology Department   (China)

^d Help Institute   (Malaysia)

Author keywords

Diagnostic efficiency; Interleukin 2 (IL 2); Nerve growth factor (NGF); Receiver operating characteristic (ROC); Schizophrenia

Indexed keywords

INTERLEUKIN 2; NERVE GROWTH FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AREA UNDER CURVE; DISCRIMINANT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-2; MALE; NERVE GROWTH FACTOR; ROC CURVE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 80051675849     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.12.017     Document Type: Article

References (62)

1. Aloe L., Alleva E., Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacology, Biochemistry, and Behavior 2002, 73:159-166.
2. Anisman H., Merali Z., Poulter M.O., Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Current Pharmaceutical Design 2005, 11(8):963-972.
3. Angelucci F., Mathe A.A., Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Progress in Brain Research 2004, 146:151-165.
4. Brodie C., Gelfand E.W. Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2. Journal of Immunology 1992, 148:3492-3497.
5. Buckley P.F., Mahadik S.P., Pillai A., Terry A.V. Neurotrophins and schizophrenia. Schizophrenia Research 2007, 94:1-11.
6. Capuron L., Ravaud A., Gualde N., Bosmans E., Dantzer R., Maes M., Neveu P.J. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26(8):797-808.
7. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Adorni A., Pegoraro M., Bosis S., Colombo F., Trabattoni D., Zagliani A., Clerici M. Cytokine profiles in schizophrenic patients treated with risperidone: a 3month follow-up study. Progress in Neuro-psychopharmacology and Biological Psychiatry 2002, 26(1):33-39.
8. Cox E.D., Hoffmann S.C., DiMercurio B.S., Wesley R.A., Harlan D.M., Kirk A.D., Blair P.J. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001, 72(4):720-726.
9. Cradock J., Young A.S., Sullivan G. The accuracy of medical record documentation in schizophrenia. Journal of Behavioral Health Services and Research 2001, 28(4):456-465.
10. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Medicine 2004, 5(1):11-25.
11. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biological Psychiatry 2006, 59(12):1116-1127.
12. Durany N., Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. European Psychiatry 2004, 19(6):326-337.
13. Dwivedi Y., Mondal A.C., Rizavi H.S., Conley R.R. Suicide brain is associated with decreased expression of neurotrophins. Biological Psychiatry 2005, 58(4):315-324.
14. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs Brain. Behavior, and Immunity 2006, 20(6):532-545.
15. Ganguli R., Rabin B.S., Kelly R.H., Lyte M., Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Annals of the New York Academy of Science 1987, 496:676-850.
16. Ganguli R., Rabin B.S., Belle S.H. Decreased interleukin-2 production in schizophrenic patients. Biological Psychiatry 1989, 26:427-430.
17. Ganguli R., Brar J.S., Chengappa K.N.R., DeLeo M., Yang Z.W., Shurin G., Rabin B.S. Mitogen-stimulated IL-2 production in never-medicated first-episode schizophrenic symptoms. Archives of General Psychiatry 1995, 52(8):668-672.
18. Garver D.L., Kelly K., Fried K.A., Magnusson M., Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses. Psychological Medicine 1988, 18:873-886.
19. Garver D.L., Nair T.R., Christensen J.D., Holcomb J., Ramberg J., Kingsbury S. Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response. Neuropsychopharmacology 1999, 21(1):82-92.
20. Garver D.L., Holcomb J.A., Christensen J.D. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry 2000, 61(12):964-972.
21. Graver D.L., Tamas R.L., Holcomb J.A. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 2003, 28(8):1515-1520.
22. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
23. Herbert T.B., Cohen S. Depression and immunity: a meta-analytic review. Psychological Bulletin 1993, 113:472-486.
24. Hernández M.E., Mendieta D., Martínez-Fong D., Loría F., Moreno J., Estrada I., Bojalil R., Pavón L. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. European Neuropsychopharmacology 2008, 18(12):917-924.
25. Hoffmann S.C., Stanley E.M., Cox E.D., DiMercurio B.S., Koziol D.E., Harlan D.M., Kirk A.D., Blair P.J. Ethnicity greatly influences cytokine gene polymorphism distribution. American Journal of Transplantation 2002, 2(6):560-567.
26. Huberty C.J., Hussein M.H. Some problems in reporting use of discriminant analysis. Journal of Experimental Education 2003, 71(2):177-191.
27. Jockers-Scherübl M.C., Rentzsch J., Danker-Hopfe H., Radzei N., Schürer F., Bahri S., Hellweg R. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neuroscience Letters 2006, 400(3):262-266.
28. Jockers-Scherübl M.C., Matthies U., Danker-Hopfe H., Lang U.E., Mahlberg R., Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. Journal of Psychopharmacology 2003, 17(4):439-445.
29. Kale A., Joshi S., Pillai A., Naphade N., Raju M.S.V.K., Nasrallah H., Mahadik S.P. Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients. Schizophrenia Research 2009, 115(2):209-214.
30. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research 2002, 109(2):143-148.
31. Kay S., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-275.
32. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Archives of General Psychiatry 2001, 58(2):165-171.
33. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. American Journal of Psychiatry 2000, 157(5):683-694.
34. Lee B.H., Kim Y.K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology 2009, 59:51-58.
35. Le-Niculescu H., Kurian S.M., Yehyawi N., Dike C., Patel S.D., Edenberg H.J., Tsuang M.T., Sslomon D.R., urnberer J.J., Niculescu A.B. Identifying blood biomarkers for mood disorders using convergent functional genomics. Molecular Psychiatry 2009, 14(2):156-174.
36. Levi-Montalcini R., Dal Toso R., Della Valle F., Skaper S.D., Leon A. Update of the NGF saga. Journal of Neurological Science 1995, 130:119-127.
37. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Progress in Neuropsychopharmacology and Biological Psychiatry 1995, 19:11-38.
38. Merali Z., Levac C., Anisman H. Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice. Biological Psychiatry 2003, 54(5):552-565.
39. Müller N. Role of the cytokine network in the CNS and psychiatric disorders. Der Nervenarzt 1997, 68(1):11-20.
40. Müller N., Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Progress in Neuropsychopharmacology and Biological Psychiatry 1998, 22(1):1-33.
41. Nassberger L., Traskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatrica Scandinavica 1993, 88(1):48-52.
42. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34(1):13-25.
43. Niv N., Cohen A.N., Mintz J., Ventura J., Young A.S. The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophrenia Research 2007, 90(1-3):245-250.
44. Otten U., Erhand P., Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proceedings of the National Academy of Sciences USA 1989, 86:10059-10063.
45. Pavón L., Sandoval-López G., Eugenia Hernández M., Loría F., Estrada I., Pérez M., Moreno J., Avila U., Leff P., Antón B., Heinze G. Th2 cytokine response in Major Depressive Disorder patients before treatment. Journal of Neuroimmunology 2006, 172(1-2):156-165.
46. Parikh V., Evans D.R., Khan M.M., Mahadik S.P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophrenia Research 2003, 60(2):117-123.
47. Perez-Polo J.R., Dy P., Westlund K., Hall K., Livingston K. Levels of serum nerve growth factor in schizophrenia. Birth Defects Original Article Series 1978, 14(5):311-321.
48. Pulver A.E. Search for schizophrenia susceptibility genes. Biological Psychiatry 2000, 47(3):221-230.
49. Sarro S., Duenas R.M., Ramirez N., Arranz B., Martinez R., Sanchez J.M., González J.M., Saló L., Miralles L., San L. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophrenia Research 2004, 68(2):349-356.
50. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47(1):1-5.
51. Siris S.G. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophrenia Bulletin 1991, 17(1):75-98.
52. Shoval G., Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. European Neuropsychopharmacology 2005, 15(3):319-329.
53. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., Stefanis C.N. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophrenia Research 2001, 47(1):13-25.
54. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity, and immune system dysregulation: A comprehensive model updated and revisited. Journal of Autoimmunity 2006, 27(2):71-80.
55. Takebayashi M., Hisaoka K., Nishida A., Tsuchioka M., Miyoshi I., Kozuru T., Hikasa S., Okamoto Y. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. The International Journal of Neuropsychopharmacology 2006, 9(5):607-612.
56. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Molecular Psychiatry 2000, 5(3):293-300.
57. Thorpe L.W., Perez-Polo J.R. The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. Journal of Neuroscience Research 1987, 18(1):134-139.
58. Torica M., Bracci-Laudiero L., Lucibello M., Nencioni L., Labardi D., Rubartelli A., Cozzolino F., Aloe L., Garaci E. Nerve growth factor is an autocrine survival factor for memory B-lymphocytes. Cell 1996, 85(3):345-356.
59. Tsuang M.T., Nossova N., Yager T.D., Tsuang M.M., Guo S.C., Shyu K.G. Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. American Journal of Medical Genetics: Part B, Neuropsychiatric Genetics 2005, 133B(1):1-5.
60. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6, and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophrenia Research 2002, 57(2):247-258.
61. Zhang X.Y., Zhou D.F., Qi L.Y., Chen S., Cao L.Y., Chen D.C., Xiu M.H., Wang F., Wu G.Y., Lu L., Kosten T.A., Kosten T.R. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology 2009, 204(1):177-184.
62. Young A.S., Mintz J., Cohen A.N. Using information systems to improve care for persons with schizophrenia. Psychiatric Services 2004, 55(3):253-255.